PDF(Pubmed)
Abstract：
UNASSIGNED: Temporomandibular disorder (TMD) is a common condition that frequently transitions to chronic symptoms. Experimental pain models that mimic the symptoms of clinical TMD may be useful in understanding the mechanisms, and sex differences, present in this disorder. Here we aimed to comprehensively characterise the nature and time-course of pain, functional impairment and hyperalgesia induced by repeated intramuscular injection of nerve growth factor (NGF) into the masseter muscle, and to investigate sex differences in the NGF-induced pain experience.
UNASSIGNED: 94 healthy individuals participated in a longitudinal study with 30-day follow-up. NGF was injected into the right masseter muscle on Day 0 and Day 2. Participants attended laboratory sessions to assess pain (Numerical Rating Scale; NRS), functional limitation (mouth opening distance, Jaw Functional Limitation Scale; JFLS) and mechanical sensitization (pressure pain thresholds; PPTs) on Days 0, 2 and 5 and completed twice daily electronic pain dairies from Day 0 to day 30.
UNASSIGNED: Peak pain averaged 2.0/10 (95 % CI: 1.6-2.4) at rest and 4.3/10 (95 % CI: 3.9-4.8) on chewing. Pain-free mouth opening distance reduced from 5.0 cm (95 % CI: 4.8-5.1 cm) on Day 0 to 3.7 cm (95 % CI: 3.5-3.9 cm) on Day 5. The greatest reduction in PPTs was observed over the masseter muscle. Females experienced higher pain, greater functional impairment, and greater sensitivity to mechanical stimuli than males.
UNASSIGNED: Intramuscular injection of NGF is a useful model with which to explore the mechanisms, and sex differences, present in clinical TMD.
UNASSIGNED: 94 healthy individuals participated in a longitudinal study with 30-day follow-up. NGF was injected into the right masseter muscle on Day 0 and Day 2. Participants attended laboratory sessions to assess pain (Numerical Rating Scale; NRS), functional limitation (mouth opening distance, Jaw Functional Limitation Scale; JFLS) and mechanical sensitization (pressure pain thresholds; PPTs) on Days 0, 2 and 5 and completed twice daily electronic pain dairies from Day 0 to day 30.
UNASSIGNED: Peak pain averaged 2.0/10 (95 % CI: 1.6-2.4) at rest and 4.3/10 (95 % CI: 3.9-4.8) on chewing. Pain-free mouth opening distance reduced from 5.0 cm (95 % CI: 4.8-5.1 cm) on Day 0 to 3.7 cm (95 % CI: 3.5-3.9 cm) on Day 5. The greatest reduction in PPTs was observed over the masseter muscle. Females experienced higher pain, greater functional impairment, and greater sensitivity to mechanical stimuli than males.
UNASSIGNED: Intramuscular injection of NGF is a useful model with which to explore the mechanisms, and sex differences, present in clinical TMD.
摘要：
未经证实：颞下颌关节紊乱病（TMD）是一种常见病，经常转变为慢性症状。模拟临床TMD症状的实验性疼痛模型可能有助于理解机制。和性别差异，出现在这种混乱中。在这里，我们旨在全面描述疼痛的性质和时间过程，向咬肌反复肌肉注射神经生长因子（NGF）引起的功能障碍和痛觉过敏，并调查NGF引起的疼痛经历中的性别差异。
UNASSIGNED：94名健康个体参与了一项30天随访的纵向研究。在第0天和第2天,将NGF注射到右咬肌。参与者参加了评估疼痛的实验室会议（数字评定量表；NRS），功能限制(开口距离，第0、2和5天的颌骨功能限制量表；JFLS）和机械致敏（压力疼痛阈值；PPTs），并从第0天到第30天每天两次完成电子疼痛护理。
非ASSIGNED：休息时疼痛峰值平均为2.0/10（95％CI：1.6-2.4），咀嚼时平均为4.3/10（95％CI：3.9-4.8）。无痛张口距离从第0天的5.0cm(95%CI:4.8-5.1cm)减少到第5天的3.7cm(95%CI:3.5-3.9cm)。在咬肌上观察到PPTs的最大减少。女性经历了更高的疼痛，更大的功能损害，对机械刺激的敏感度高于男性。
UNASSIGNED：肌内注射NGF是探索机制的有用模型，和性别差异，目前在临床TMD。
UNASSIGNED：94名健康个体参与了一项30天随访的纵向研究。在第0天和第2天,将NGF注射到右咬肌。参与者参加了评估疼痛的实验室会议（数字评定量表；NRS），功能限制(开口距离，第0、2和5天的颌骨功能限制量表；JFLS）和机械致敏（压力疼痛阈值；PPTs），并从第0天到第30天每天两次完成电子疼痛护理。
非ASSIGNED：休息时疼痛峰值平均为2.0/10（95％CI：1.6-2.4），咀嚼时平均为4.3/10（95％CI：3.9-4.8）。无痛张口距离从第0天的5.0cm(95%CI:4.8-5.1cm)减少到第5天的3.7cm(95%CI:3.5-3.9cm)。在咬肌上观察到PPTs的最大减少。女性经历了更高的疼痛，更大的功能损害，对机械刺激的敏感度高于男性。
UNASSIGNED：肌内注射NGF是探索机制的有用模型，和性别差异，目前在临床TMD。
